SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH H impact

MRK: Approves KEYTRUDA

European Commission approves KEYTRUDA plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer

MRK

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.